CROSS-STANDARD public interest · Home/clinical medical device

China-to-Brazil Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical electromedical device documentation against Brazil ANVISA RDC 751/2022 classification (Classes I–IV), registro vs notificação pathways, Brazilian GMP (B-GMP, RDC 665/2022), INMETRO electromedical certification (ABNT NBR IEC 60601-1), clinical/safety evidence requirements, Brazilian Registration Holder (BRH) obligations, and Portuguese-language labelling and UDI/traceability requirements.

Dataset 2026-06-11 Last verified 2026-06-12 6 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline Brazil (ANVISA) Gap / action Source + verification date
Market Authorization and Risk Classification — ANVISA RDC 751/2022 (Classes I–IV) China NMPA classifies medical devices into three classes under the 2021 Administrative Measures (NMPA Order No. 47): Class I (lowest risk, filing/备案 only with provincial NMPA), Class II (moderate risk, registration/注册 with provincial NMPA), and Class III (highest risk, national NMPA registration). Classification uses the NMPA Classification Catalogue (分类目录). Home-use electromedical equipment typically falls in Class II; clinical electromedical equipment commonly reaches Class II or III. NMPA registration certificates are not recognised by ANVISA and cannot be submitted in lieu of a Brazil registro or notificação.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
医疗器械分类目录 (NMPA Announcement No. 104, 2017; amended by subsequent announcements)
医疗器械监督管理条例 (State Council Order No. 739, 2021)		 ANVISA Resolution RDC 751/2022 (in force from 28 February 2023) governs the classification and essential requirements of medical devices (produtos para saúde) in Brazil. Devices are classified into four risk classes: Class I (lowest risk), Class II (moderate risk), Class III (moderately high risk), and Class IV (highest risk). Classification criteria are based on intended use, duration of contact, invasiveness, and whether the device delivers energy or medicinal substances — criteria largely harmonised with GHTF/IMDRF principles. Electromedical equipment (active devices supplying energy) is generally Class II to IV. Market access route depends on class: Class I and II devices may proceed via notificação (notification, lower scrutiny); Class III and IV devices require registro (registration, full technical dossier review). The classification determines which ANVISA pathway, fee category, and dossier format applies. Importers must work through a Brazilian Registration Holder (BRH) that is a legal entity established in Brazil.ANVISA RDC 751/2022 — Classificação de Produtos para a Saúde (in force 2023-02-28)
ANVISA RDC 185/2001 (superseded by RDC 751/2022 for classification) — verify current consolidated version on ANVISA portal
Lei 6.360/1976 and Decreto 8.077/2013 — framework for health product regulation in Brazil
ANVISA ANUIES e PETICIONAMENTO — Sisvar/Datavisa petitioning system for registro and notificação		 Brazil uses a four-class system (I–IV) vs. China's three-class system (I–III). The same electromedical device may receive different risk classes under each framework. A NMPA Class II device may be ANVISA Class III or IV (triggering mandatory registro with full dossier review), or Class I/II (permitting notificação). NMPA registration provides no direct equivalence under ANVISA rules. Manufacturers must independently determine the ANVISA class under RDC 751/2022 rules. Misclassification leads to wrong pathway selection, potentially invalidating market authorization. The registro route for Class III/IV electromedical devices is substantially more demanding than notificação.[INFORMATIONAL ONLY] Manufacturers must independently determine the correct ANVISA risk class under RDC 751/2022 for each device before selecting a market-access pathway. NMPA class cannot be mapped directly. Electromedical devices (active energy-delivering) will typically require at minimum a Class II notificação or, for Class III/IV, a full registro with technical dossier. Engage a qualified Brazilian regulatory affairs consultant to determine class and pathway. This is not legal or regulatory advice. ANVISA — Agência Nacional de Vigilância Sanitária (Brazil)2026-06-12 · unverified
Clinical and Safety Evidence — ANVISA Technical Dossier Requirements for Registro For NMPA registration of Class II and III medical devices, China requires submission of a technical dossier including: product description, intended use, standards compliance, risk analysis (per YY/T 0316, aligned to ISO 14971), electrical safety test reports (GB 9706.1-2020), and clinical evidence. Clinical evidence for NMPA may consist of clinical trials conducted in China or clinical evaluation based on equivalent devices or literature review, per NMPA guidance. NMPA registration dossiers are in Chinese (Mandarin) and follow NMPA-specific formats. An ISO 13485 / NMPA GMP certificate is required for Class II and III. NMPA-registered devices have undergone a comparable rigorous review, but the documentation format, language, and specific requirements differ from ANVISA's.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
YY/T 0316-2016 (ISO 14971:2007 equivalent) — Risk Management for Medical Devices
医疗器械临床评价技术指导原则 (NMPA Clinical Evaluation Guidance, 2021)
GB 9706.1-2020 — Medical electrical equipment safety standard		 For Class III and IV medical devices undergoing ANVISA registro (registration), a technical dossier (Dossiê Técnico) must be submitted demonstrating safety and efficacy. ANVISA's requirements include: (1) Product description and intended use; (2) Risk analysis and risk management documentation (aligned to ISO 14971); (3) Electrical safety test reports (ABNT NBR IEC 60601-1 and applicable particular standards); (4) INMETRO certification evidence; (5) Clinical evidence — ANVISA may accept published clinical literature, post-market clinical data, clinical investigations, or equivalence arguments; for novel or high-risk Class IV devices, clinical investigation data may be required; (6) B-GMP certificate; (7) Labelling samples and Instructions for Use (IFU) in Portuguese; (8) Summary of Safety and Clinical Performance (SSCP) concept is being progressively adopted following international alignment. For Class I/II notificação, a shorter declaration-based process applies but the device must still comply with all applicable technical standards. ANVISA review timelines for registro vary; complex Class IV devices may take 18–36 months. Fees (taxa de fiscalização de vigilância sanitária — TFVS) apply and are substantial.ANVISA RDC 751/2022 — Requisitos Essenciais de Segurança e Desempenho (RESD) for medical devices
ANVISA RDC 185/2001 and subsequent resolutions governing registro dossier format (verify current consolidated requirements at gov.br/anvisa)
ISO 14971:2019 — Medical devices — Application of risk management to medical devices (referenced by ANVISA for risk documentation)
ANVISA Instrução Normativa (IN) governing clinical evidence requirements — verify current edition on gov.br/anvisa		 Key gaps: (1) ANVISA technical dossier must be submitted in Portuguese and follow ANVISA-specific formats — NMPA dossiers in Chinese cannot be submitted directly; full translation and reformatting is required; (2) ANVISA may require Brazil-specific clinical evidence or additional evidence for novel/high-risk devices not covered by NMPA registration; (3) Risk management documentation must align to ISO 14971 and reference ANVISA Essential Requirements (RESD under RDC 751/2022); (4) ANVISA registro review times are independent of NMPA timelines and can extend 18–36 months for Class IV; (5) TFVS registration fees are substantial and must be budgeted; (6) Any post-registration changes require ANVISA notification or amendment — NMPA certificate updates do not automatically update ANVISA registration; (7) Post-market vigilance reports to ANVISA have specific Brazilian deadlines and formats.[INFORMATIONAL ONLY] Chinese manufacturers with existing NMPA dossiers have a substantive technical foundation (risk management, safety testing, clinical evidence) but must fully reformat, translate to Portuguese, and adapt all documentation to ANVISA registro requirements under RDC 751/2022. Clinical evidence accepted by NMPA may satisfy ANVISA requirements for most device types, but novel or high-risk Class IV devices may require additional Brazil-specific evidence. Budget for TFVS fees and plan for 18–36 month review timelines for complex Class IV devices. This is not legal or regulatory advice; consult a qualified Brazilian regulatory affairs specialist. ANVISA — Agência Nacional de Vigilância Sanitária (Brazil)2026-06-12 · unverified
Labelling, Portuguese Language, and UDI Requirements NMPA requires Chinese-language labelling for all medical devices sold in China, including product name, manufacturer, registration/filing number, intended use, warnings, lot number, manufacturing/expiry date, and storage conditions. For export, Chinese manufacturers typically produce separate Chinese-labelled versions for domestic sale and export versions with target-market labelling. China implemented UDI requirements progressively from 2021 under NMPA Order No. 66 (Administrative Measures for Unique Device Identification of Medical Devices), requiring UDI coding for Class III devices from 2022, Class II from 2023, and Class I over a longer transition. Chinese UDI codes (based on GS1 or HIBC standards) are not the same as ANVISA's traceability system and cannot be submitted in lieu of ANVISA traceability requirements.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) — labelling requirements
医疗器械说明书和标签管理规定 (CFDA Order No. 6, 2014) — labelling and IFU rules
医疗器械唯一标识管理办法 (NMPA Order No. 66, 2019) — China UDI system		 All medical devices commercialised in Brazil must carry labelling and an Instructions for Use (IFU) in Portuguese (Brazilian Portuguese). Labelling requirements are governed by ANVISA regulations and include at minimum: product name, manufacturer name and address, BRH name and ANVISA registration/notification number, intended use, warnings and contraindications, sterility status (if applicable), expiry or manufacturing date, lot/serial number, storage and handling conditions, INMETRO mark (for electromedical equipment requiring compulsory certification), and ANVISA registration number (número de registro ANVISA). For electromedical equipment, the IFU must be in Portuguese and accompany the product. Regarding UDI (Unique Device Identification): ANVISA has been progressively implementing a UDI-equivalent traceability system. As of 2026, ANVISA's SCTIE/SAVI (Rastreabilidade) initiative requires traceability codes for higher-risk devices (Class III/IV). Verify current UDI/traceability obligations on the ANVISA portal as requirements are being phased in over 2023–2026. Chinese labelling alone is not acceptable; re-labelling in Brazil or factory Portuguese labelling is required.ANVISA RDC 751/2022 — Requisitos Essenciais including labelling obligations for medical devices
ANVISA RDC 185/2001 and successors — labelling and IFU requirements for registered medical devices (verify current consolidated requirements at gov.br/anvisa)
INMETRO labelling requirements for electromedical equipment under applicable INMETRO Portaria
ANVISA Rastreabilidade / SCTIE-SAVI UDI/traceability phased implementation (verify current phase and applicable device classes on gov.br/anvisa)		 Key gaps: (1) All product labelling and IFU must be in Brazilian Portuguese — Chinese or English labelling alone is not acceptable; either re-labelling in Brazil or factory-produced Portuguese labelling is required; (2) ANVISA registration number (número de registro) and BRH information must appear on the label — these are only obtained after ANVISA registration is granted, meaning labelling cannot be finalised until registration is complete; (3) INMETRO mark must appear on electromedical equipment labels; (4) ANVISA is phasing in UDI/traceability requirements for higher-risk devices — verify current phase for the specific device class on the ANVISA portal; (5) Labels submitted as part of the registro dossier must match the actual commercial labels — post-approval label changes require ANVISA notification; (6) Chinese characters on labels may be acceptable alongside Portuguese but Portuguese must be the primary language; consult current ANVISA guidance.[INFORMATIONAL ONLY] Chinese manufacturers must plan for complete Portuguese-language labelling and IFU from the outset. Because the ANVISA registration number and BRH details can only be added to labels after registration is granted, manufacturers often use a two-step approach: register with draft label samples, then produce final commercial labels post-approval. INMETRO mark placement must be confirmed with the OCP. Verify current ANVISA UDI/traceability phase-in requirements on gov.br/anvisa before finalising labelling strategy. This is not legal or regulatory advice; consult a qualified Brazilian regulatory affairs specialist. ANVISA — Agência Nacional de Vigilância Sanitária (Brazil)2026-06-12 · unverified
Quality Management System / Brazilian GMP (B-GMP) — ANVISA RDC 665/2022 China NMPA requires compliance with the Medical Device Good Manufacturing Practice (医疗器械生产质量管理规范, GMP) for all licensed medical device manufacturers. The current edition is NMPA Order No. 64 (2014), with a new edition issued as NMPA Order No. 107 (November 2025, effective November 2026). Many Chinese manufacturers also hold ISO 13485:2016 certification. Chinese GMP and ISO 13485 provide a strong QMS foundation, but NMPA GMP certificates are not automatically accepted by ANVISA as B-GMP equivalents. China does not currently have a formal bilateral GMP recognition agreement with ANVISA for medical devices (verify current status on ANVISA portal).医疗器械生产质量管理规范 (NMPA GMP, Order No. 64, 2014; superseded by Order No. 107, effective Nov 2026)
ISO 13485:2016 (widely adopted by Chinese exporters, YY/T 0287-2017 equivalent)
医疗器械监督管理条例 (State Council Order No. 739, 2021)		 ANVISA Resolution RDC 665/2022 (Boas Práticas de Fabricação — BPF, also referred to as Brazilian GMP or B-GMP for medical devices) establishes Good Manufacturing Practice requirements for medical device manufacturers supplying the Brazilian market. For Class III and Class IV devices, a B-GMP certificate issued by ANVISA (or a recognised foreign GMP authority under a bilateral agreement, if applicable) is mandatory as part of the registro dossier. For Class I and II devices (notificação), B-GMP is strongly recommended and may be required depending on device type. B-GMP is based largely on ISO 13485:2016 principles and covers facility inspection, document control, production controls, traceability, CAPA, and post-market surveillance. Foreign manufacturers must have their facility inspected either by ANVISA directly or provide GMP evidence accepted under ANVISA's international recognition framework. ISO 13485 certification from an accredited certification body is not automatically equivalent to an ANVISA B-GMP certificate, but supports the application. Verify current B-GMP recognition agreements on ANVISA portal.ANVISA RDC 665/2022 — Boas Práticas de Fabricação de Produtos para a Saúde (B-GMP for medical devices)
ANVISA RDC 16/2013 (predecessor BPF resolution, superseded for most device types by RDC 665/2022 — verify transition status)
ISO 13485:2016 — Medical Devices Quality Management Systems (supporting evidence for B-GMP applications)
ANVISA International GMP Recognition Framework (verify current bilateral recognition agreements at gov.br/anvisa)		 Key gaps: (1) B-GMP certificate under RDC 665/2022 is mandatory for Class III/IV registro — NMPA GMP compliance alone does not satisfy this requirement; (2) China does not have a formal bilateral GMP recognition agreement with ANVISA for medical devices as of 2026 (verify current status); (3) Foreign manufacturers typically need an ANVISA facility inspection or must submit evidence through ANVISA's international recognition process — this adds cost and lead time; (4) ISO 13485 certification supports but does not replace B-GMP certification; (5) ANVISA may require Portuguese-language quality documentation or translations; (6) Post-market vigilance reporting to ANVISA (notificação de queixas técnicas e eventos adversos) has specific Brazilian requirements not captured by NMPA GMP.[INFORMATIONAL ONLY] Chinese manufacturers targeting Brazil must obtain a B-GMP certificate under ANVISA RDC 665/2022 for Class III/IV devices. Existing ISO 13485 and NMPA GMP compliance is a strong foundation but does not substitute for ANVISA certification. Early engagement with ANVISA on the inspection or recognition pathway is essential given typical review timelines. This is not legal or regulatory advice; consult a qualified Brazilian regulatory affairs specialist. ANVISA — Agência Nacional de Vigilância Sanitária (Brazil)2026-06-12 · unverified
Brazilian Registration Holder (BRH) — Mandatory Local Legal Entity For domestic Chinese market access, NMPA registration is held directly by the manufacturer (domestic) or by the Chinese importer/agent (foreign manufacturer). For imported devices, the foreign manufacturer typically partners with a Chinese agent or subsidiary to hold the NMPA registration. This is structurally similar to the BRH requirement in Brazil — both require a local legal entity to hold the market authorization. However, the NMPA registration holder and ANVISA BRH are separate entities in different jurisdictions; the Chinese NMPA agent/importer cannot serve as the Brazilian BRH.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) — importer/agent registration holder provisions
医疗器械监督管理条例 (State Council Order No. 739, 2021)		 Brazilian law requires that all medical devices commercialised in Brazil be registered or notified in the name of a Brazilian Registration Holder (BRH) — a legal entity incorporated and registered in Brazil (typically an importer, distributor, or subsidiary). The foreign manufacturer cannot directly hold an ANVISA registro or notificação; the BRH is the entity legally responsible before ANVISA for the product's compliance, safety, vigilance reporting, product recalls, and all regulatory correspondence. The BRH must maintain the product file and regulatory documentation in Brazil and must hold a valid ANVISA operating licence (Autorização de Funcionamento da Empresa — AFE) for importing and distributing medical devices. The BRH relationship must be formalised in a contractual agreement between the foreign manufacturer and the BRH. The manufacturer must authorise the BRH in writing to act on its behalf for ANVISA purposes.Lei 6.360/1976 — Surveillance of pharmaceutical, cosmetic, cleaning, and medical device products; imposes local holder requirement
ANVISA RDC 185/2001 and successors — registro requirements imposing BRH obligation
ANVISA — Autorização de Funcionamento da Empresa (AFE) requirement for importers/distributors of medical devices
Decreto 8.077/2013 — implementing regulation for health product registration in Brazil		 Key gaps: (1) A dedicated Brazil-incorporated BRH must be identified or established before ANVISA registration can proceed — the foreign Chinese manufacturer cannot self-register; (2) The BRH must hold a valid ANVISA AFE licence covering medical device import and distribution; (3) The BRH bears full regulatory liability in Brazil for product safety and vigilance — this requires careful contractual structuring to allocate responsibilities between manufacturer and BRH; (4) Finding a reputable BRH with existing ANVISA infrastructure adds lead time and ongoing compliance cost; (5) All regulatory correspondence, recalls, and vigilance reports flow through the BRH — the manufacturer must maintain responsive communication with the BRH; (6) Changes to the BRH relationship or BRH identity require ANVISA notification and may trigger a new registration process.[INFORMATIONAL ONLY] Identifying and contracting a qualified BRH with a valid ANVISA AFE licence is one of the first and most critical steps for any Chinese manufacturer targeting the Brazilian market. The BRH bears regulatory liability in Brazil and must be carefully selected. Contractual agreements must clearly allocate responsibilities for vigilance, recalls, and regulatory correspondence. The manufacturer must maintain responsive communication with the BRH throughout the product lifecycle. This is not legal advice; consult a qualified Brazilian legal and regulatory affairs specialist. ANVISA — Agência Nacional de Vigilância Sanitária (Brazil)2026-06-12 · unverified
Electromedical Safety — ABNT NBR IEC 60601-1 and INMETRO Certification GB 9706.1-2020 is China's mandatory national standard for general electrical safety of medical electrical equipment, adopted from IEC 60601-1 Ed.3 with minor Chinese deviations, mandatory for new NMPA registrations from 2023-05-01. Chinese manufacturers also commonly hold YY standard certificates for particular standards (YY/T equivalents of IEC 60601-2-x). NMPA-designated laboratory testing to GB 9706.1-2020 is required for NMPA registration. Because both ABNT NBR IEC 60601-1 and GB 9706.1-2020 derive from IEC 60601-1 Ed.3, a substantial portion of test data (leakage current, dielectric withstand, insulation classification) can be shared, but a separate INMETRO OCP test campaign and certification process is still required for Brazil.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01)
YY/T standards series (particular standards, IEC 60601-2-x equivalents)
NMPA Medical Device Registration Regulations (Order No. 47, 2021)		 Brazil requires electromedical equipment (equipamentos eletromédicos) to comply with ABNT NBR IEC 60601-1 — the Brazilian adoption of IEC 60601-1 (current edition aligned to IEC 60601-1 Ed.3.1) — as the mandatory electrical safety standard. In addition, INMETRO (Instituto Nacional de Metrologia, Qualidade e Tecnologia) mandates product certification (Certificação Compulsória) for electromedical equipment under the INMETRO Portaria system. The applicable Portaria requires testing at an INMETRO-accredited OCP (Organismo de Certificação de Produto) and an INMETRO-accredited laboratory. Certification is issued for the product model and must be renewed or updated upon specification changes. The INMETRO mark must appear on the product and packaging. Applicable particular standards (ABNT NBR IEC 60601-2-x series) may also apply depending on device type. Verify the specific Portaria number and current OCP list on the INMETRO portal (inmetro.gov.br) as Portarias are periodically updated — the applicable Portaria for electromedical equipment has been revised over time (flag: exact current Portaria number should be verified directly on INMETRO portal as of the date of application).ABNT NBR IEC 60601-1 — Equipamento eletromédico — Parte 1: Requisitos gerais para segurança básica e desempenho essencial (Brazilian adoption of IEC 60601-1 Ed.3.1)
INMETRO Portaria (applicable Portaria for electromedical equipment — verify current number on inmetro.gov.br, as Portarias are revised periodically)
ABNT NBR IEC 60601-2-x series — particular standards for specific electromedical device types (verify applicability by device type)
INMETRO — Instituto Nacional de Metrologia, Qualidade e Tecnologia (inmetro.gov.br)		 Both ABNT NBR IEC 60601-1 and GB 9706.1-2020 derive from IEC 60601-1 Ed.3, providing significant test-data overlap. Key gaps: (1) INMETRO mandatory certification is a separate process from NMPA registration — a new INMETRO OCP engagement is required regardless of existing Chinese test certificates; (2) The INMETRO OCP must be selected from the INMETRO-accredited list, not from NMPA-designated labs; (3) INMETRO certification is model-specific and must be renewed on specification change; (4) The INMETRO mark (not a CE or NMPA mark) must appear on product and packaging; (5) The applicable INMETRO Portaria should be verified at time of application as Portarias are revised; (6) Particular standards (ABNT NBR IEC 60601-2-x) must be checked for applicability; (7) ANVISA registro also requires separate safety dossier referencing the ABNT standard — the INMETRO certificate alone does not replace the ANVISA technical dossier.[INFORMATIONAL ONLY] A device already certified to GB 9706.1-2020 (IEC 60601-1 Ed.3-based) has a strong technical overlap with ABNT NBR IEC 60601-1 requirements. However, a separate INMETRO mandatory certification must be obtained from an INMETRO-accredited OCP — existing NMPA or CB-scheme certificates do not substitute. The INMETRO Portaria number and current OCP list must be verified on inmetro.gov.br at the time of application. This is not legal or regulatory advice; engage a qualified Brazilian regulatory affairs specialist. INMETRO — Instituto Nacional de Metrologia, Qualidade e Tecnologia (Brazil)2026-06-12 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.